Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment

Sanna-Kaisa Herukka¹, Anja Hviid Simonsen², Niels Andreasen³, Ines Baldeiras⁴, Maria Bjerke⁵, Kaj Blennow⁶, Sebastiaan Engelborghs⁷, Giovanni B Frisoni⁸, Tomasz Gabryelewicz⁹, Samantha Galluzzi¹⁰, Ron Handels¹¹, Milica G Kramberger¹², Agnieszka Kulczyńska¹³, Jose Luis Molinuevo¹⁴, Barbara Mroczko¹⁵, Agneta Nordberg¹⁶, Catarina Resende Oliveira⁴, Markus Otto¹⁷, Juha O Rinne¹⁸, Uroš Rot¹², Esen Saka¹⁹, Hilkka Soininen¹, Hanne Struyfs⁵, Silvia Suardi²⁰, Pieter Jelle Visser²¹, Bengt Winblad²², Henrik Zetterberg²³, Gunhild Waldemar²⁴

Affiliations

¹ Department of Neurology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.
² Danish Dementia Research Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
³ Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden.
⁴ Neurochemistry Laboratory, Faculty of Medicine, CHUC-Coimbra University Hospital, CNC, CNC.IBILI-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
⁵ Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
⁶ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
⁷ Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium.
⁸ Geneva Neuroscience Center, University Hospitals and University of Geneva, Geneva, Switzerland; IRCCS Fatebenefratelli, Brescia, Italy.
⁹ Department of Neurodegenerative Disorders, Mossakowski Medical Research Centre Polish Academy of Sciences, Warsaw, Poland.
¹⁰ IRCCS Fatebenefratelli, Brescia, Italy.
¹¹ Alzheimer Centre Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.
¹² Center for Cognitive Impairments, Department of Neurology, University Medical Center Ljubljana, Ljubljana, Slovenia.
¹³ Department of Neurodegeneration Diagnostics, Medical University of Białystok, Białystok, Poland.
¹⁴ Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clinic i Universitari, IDIBAPS, Barcelona, Spain; Beta Brain Research Center, Fundació Pasqual Maragall, Barcelona, Spain.
¹⁵ Department of Neurodegeneration Diagnostics, Medical University of Białystok, Białystok, Poland; Department of Biochemical Diagnostics, University Hospital in Białystok, Białystok, Poland.
¹⁶ Department of NVS, Center for Alzheimer Research, Translational Alzheimer Neurobiology, Karolinska Institutet, Huddinge, Sweden.
¹⁷ Department of Neurology, University of Ulm, Ulm, Germany.
¹⁸ Turku PET Centre, Turku University Hospital and University of Turku, Turku, Finland.
¹⁹ Department of Neurology, Hacettepe University Hospitals, Ankara, Turkey.
²⁰ Neuropathology Laboratory, Neurological Institute C. Besta, Milan, Italy.
²¹ Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands; Department of Neurology, Alzheimer Centre, VUMC, Amsterdam, The Netherlands.
²² Department NVS, Karolinska Institutet, Center for Alzheimer Research, Division of Neurogeriatrics, Huddinge, Sweden.
²³ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.
²⁴ Danish Dementia Research Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Electronic address: gunhild.waldemar.01@regionh.dk.

PMID: 28341066
DOI: 10.1016/j.jalz.2016.09.009

Free article

Review

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment

Sanna-Kaisa Herukka et al. Alzheimers Dement. 2017 Mar.

Free article

. 2017 Mar;13(3):285-295.

doi: 10.1016/j.jalz.2016.09.009. Epub 2016 Oct 27.

Authors

Affiliations

¹ Department of Neurology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.
² Danish Dementia Research Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
³ Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden.
⁴ Neurochemistry Laboratory, Faculty of Medicine, CHUC-Coimbra University Hospital, CNC, CNC.IBILI-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
⁵ Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
⁶ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
⁷ Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium.
⁸ Geneva Neuroscience Center, University Hospitals and University of Geneva, Geneva, Switzerland; IRCCS Fatebenefratelli, Brescia, Italy.
⁹ Department of Neurodegenerative Disorders, Mossakowski Medical Research Centre Polish Academy of Sciences, Warsaw, Poland.
¹⁰ IRCCS Fatebenefratelli, Brescia, Italy.
¹¹ Alzheimer Centre Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.
¹² Center for Cognitive Impairments, Department of Neurology, University Medical Center Ljubljana, Ljubljana, Slovenia.
¹³ Department of Neurodegeneration Diagnostics, Medical University of Białystok, Białystok, Poland.
¹⁴ Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clinic i Universitari, IDIBAPS, Barcelona, Spain; Beta Brain Research Center, Fundació Pasqual Maragall, Barcelona, Spain.
¹⁵ Department of Neurodegeneration Diagnostics, Medical University of Białystok, Białystok, Poland; Department of Biochemical Diagnostics, University Hospital in Białystok, Białystok, Poland.
¹⁶ Department of NVS, Center for Alzheimer Research, Translational Alzheimer Neurobiology, Karolinska Institutet, Huddinge, Sweden.
¹⁷ Department of Neurology, University of Ulm, Ulm, Germany.
¹⁸ Turku PET Centre, Turku University Hospital and University of Turku, Turku, Finland.
¹⁹ Department of Neurology, Hacettepe University Hospitals, Ankara, Turkey.
²⁰ Neuropathology Laboratory, Neurological Institute C. Besta, Milan, Italy.
²¹ Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands; Department of Neurology, Alzheimer Centre, VUMC, Amsterdam, The Netherlands.
²² Department NVS, Karolinska Institutet, Center for Alzheimer Research, Division of Neurogeriatrics, Huddinge, Sweden.
²³ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.
²⁴ Danish Dementia Research Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Electronic address: gunhild.waldemar.01@regionh.dk.

PMID: 28341066
DOI: 10.1016/j.jalz.2016.09.009

Abstract

This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β_1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with mild cognitive impairment (MCI). The recommendations were developed by a multidisciplinary working group and based on the available evidence and consensus from focused group discussions for 1) prediction of clinical progression to Alzheimer's disease (AD) dementia, 2) cost-effectiveness, 3) interpretation of results, and 4) patient counseling. The working group recommended using CSF AD biomarkers in the diagnostic workup of MCI patients, after prebiomarker counseling, as an add-on to clinical evaluation to predict functional decline or conversion to AD dementia and to guide disease management. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Furthermore, the working group provided recommendations for interpretation of ambiguous CSF biomarker results and for pre- and post-biomarker counseling.

Keywords: Alzheimer's disease; Biomarkers; CSF; Diagnostics; GRADE; Mild cognitive impairment; Recommendations.

PubMed Disclaimer

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment

Affiliations

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical